Kernal is creating mRNA drugs that instruct specific cells in the body on how to make their own medicine. Messenger RNA technology has proven extremely useful in rapidly developing vaccines against COVID-19. Kernal is developing the next generation of mRNA therapy, called mRNA 2.0. It solves the critical problem of cancer cell selectivity that affects mRNA and oncolytic virus-based immuno-oncology drugs. Located in Cambridge, MA, Kernal received three awards from Amgen and NASA. With roots at MIT, Harvard, and big pharma, Kernal’s interdisciplinary team of MDs and PhDs previously built a successful biotech company and has deep expertise in the mRNA space.
Kernal is dedicated to providing a diverse work environment and is committed to equal employment opportunities for all its employees and qualified applicants. We do not discriminate in employment practices for reasons of race, color, national origin, age, gender, sexual orientation, marital or veteran status, religion, disability, or any other legally protected status. Kernal will make reasonable accommodations for qualified individuals with known disabilities by applicable law.